


Amendments to the Claims

1-9. (Cancelled)

10. (New) A combination of a compound represented by the following formula or a salt thereof (hereinafter referred to as "TZT-1027")



and an extracellular signal-regulated kinase (ERK)-mitogen-activated protein (MAP) (hereinafter referred to as "ERK-MAP") kinase cascade inhibitor, wherein TZT-1027 and the ERK-MAP kinase cascade inhibitor are administered, either simultaneously or separately with a predetermined interval of time, in order to treat a tumor.

11. (New) A combination as claimed in claim 10 wherein the ERK-MAP kinase cascade inhibitor is a MAP kinase inhibitor, a MAP kinase kinase inhibitor or a MAP kinase kinase kinase inhibitor.

12. (New) An antitumor agent which contains, as an active ingredient, TZT-1027 for use in combination with an ERK-MAP kinase cascade inhibitor.

13. (New) An agent for potentiating the antitumor effect of TZT-1027 which contains an ERK-MAP kinase cascade inhibitor as an active ingredient.

14. (New) A method for the treatment of a tumor which comprises administering a therapeutically effective amount of TZZT-1027 and an ERK-MAP kinase cascade inhibitor to a patient in need thereof, either simultaneously or separately within a predetermined interval of time.

15. (New) A method for potentiating the antitumor effect of TZZT-1027 which comprises administering TZZT-1027 in combination with an ERK-MAP kinase cascade inhibitor.

16. (New) A pharmaceutical product comprising TZZT-1027 or an ERK-MAP kinase cascade inhibitor or both, the pharmaceutical product being characterized by having, on or within the packaging material thereof, an indication or document showing the instruction that TZZT-1027 and the ERK-MAP kinase cascade inhibitor should be used in combination.